Skip to main content
. 2017 Jul 31;8(48):83792–83801. doi: 10.18632/oncotarget.19698

Figure 1.

Figure 1

Oral administration of Rg1 preserved the cardiac function in mice treated with doxorubicin on day 7 and 28 (A) Echocardiography of the heart. Upper panel, oral administration of Rg1; lower panel, oral administration of DDW. LVIDd: left ventricle internal diameter in diastole; LVIDs: left ventricle internal diameter in systole. (B) On day 0, there was no difference of FS and EF between Rg1 and DDW group. (C) Oral administration of Rg1 significantly improve FS as compared to the DDW control on day 7, n = 5, *p < 0.05; and oral administration of Rg1 significantly improves EF as compared to the DDW control on day 7, n = 5, *p < 0.01. (D) Oral administration of Rg1 significantly improved FS as compared to the DDW control on day 28, n = 5, *p < 0.05; and oral administration of Rg1 significantly improves EF as compared to the DDW control on day 28, n = 5, *p < 0.01.